阿帕替尼应用于晚期肝癌患者的临床疗效和安全性分析  

Analysis on Clinical Curative Effect and Safety of Apatinib in the Application of Patients with Advanced Liver Cancer

作　　者：朱土福[1] 黎昌国[1] ZHU Tufu,LI Changguo,(1 st Department of Oncology, Maoming People’s Hospital,Maoming 525000, Chin)

机构地区：[1]广东省茂名市人民医院肿瘤一科,广东茂名525000

出　　处：《临床医学工程》2018年第5期621-622,共2页Clinical Medicine & Engineering

摘　　要：目的探讨阿帕替尼应用于晚期肝癌患者的临床疗效和安全性。方法选取我院2015年3月至2017年9月期间收治的86例晚期肝癌患者,根据治疗方法分为阿帕替尼组和对照组各43例。对照组采用安慰剂和支持治疗,阿帕替尼组在此基础上采用阿帕替尼治疗。比较两组患者的近期疗效、中位无进展生存周期(PFS)和不良反应发生率。结果阿帕替尼组的DCR和ORR分别为20.93%、51.16%,均明显高于对照组的11.63%、37.21%(P<0.05)。阿帕替尼组的中位PFS为4.83个月,明显长于对照组的2.65个月(P<0.05)。两组患者的不良反应发生率比较无统计学差异(P>0.05)。结论采用阿帕替尼治疗晚期肝癌,效果显著,能够明显延长患者的生存周期,具有一定的安全性,值得临床推广。Objective To study the clinical curative effect and safety of apatinib in the application of patients with advanced liver cancer. Methods 86 cases of patients with advanced liver cancer admitted to our hospital from March 2015 to September 2017 were selected and divided into apatinib group and control group according to the treatment methods, with 43 cases in each group. The control group received placebo and supportive treatment, while the apatinib group was treated with apatinib on the basis of the control group. The short-term curative effect, median progression-free survival（PFS） and incidence of adverse reactions were compared between the two groups. Results The DCR and ORR of the apatinib group were 20.93% and 51.16% respectively, significantly higher than 11.63% and 37.21% of the control group（P 〈0.05）. The median PFS of the apatinib group was 4.83 months, significantly longer than that 2.65 months of the control group（P 〈0.05）. No statistical difference was found in the incidence of adverse reactions between the two groups（P 〉0.05）.Conclusions Apatinib in the treatment of advanced liver cancer has significant effect, can significantly prolong the life cycle of patients with certain safety, which is worthy of clinical promotion.

关 键 词：阿帕替尼 晚期肝癌 疗效 安全性 

分 类 号：R735.7[医药卫生—肿瘤]